General Drug Use-Results Survey of Onoact [ ventricular fibrillation and hemodynamically ventricular tachycardia]

General Drug Use-Results Survey of Onoact [Following the refractory and urgent fatal arrhythmia: ventricular fibrillation and hemodynamically unstable ventricular tachycardia ]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080225340

Enrollment

200

Registered

2020-08-24

Start date

2019-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular arrhythmias

Interventions

investigational material(s) Generic name etc : Onoact for Infusion 50mg Onoact for Infusion 100mg INN of investigational material : landiolol Therapeutic category code : 212 Antiarrhythmic agents Dosa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients will be registered as subjects in this survey if they are the following refractory and urgent fatal arrhythmia: ventricular fibrillation and hemodynamically unstable ventricular tachycardia, which is specified as indication of the drug, and they have no previous history of treatment with the drug on this indication.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety items : Occurrence of adverse drug reactions set as safety specifications, factors considered to influence the safety Efficacy items : comprehensive evaluation, patient outcomes (survival rate) at 168 hours after the start of landiolol treatment, factors considered to influence the efficacy	—

Countries

Japan

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-662225501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026